OrbiMed, Novartis Venture Fund and RA Capital Management have joined forces to fund and help launch GentiBio.

The Boston, Massachusetts-based biotech starts life with a $20 million seed funding with an aim of creating new engineered regulatory T cells to deliver immune tolerizing meds for autoimmune, allergic and inflammatory diseases.

GentiBio lands with tech out of the Seattle Childrens Research Institute, Benaroya Research Institute and MIGAL Galilee Research Institute.

September 2-3, 2020 Live, Online Course: Biopharma Revenue Forecasting that Drives Decision Making and Investments

Become fluent in the core elements of revenue forecasting including epidemiology, competitive assessments, market share assignment and pricing. Let Biotech Primer's dynamic industry experts teach you how to assess the value of new therapies.

The biotech was in fact co-founded by a team of scientists from these three institutes to restore immune tolerance using Treg cell therapy engineered with novel technologies that direct potent EngTregs to specific tissues damaged by abnormal immune responses, said the biotech in a statement.

The hope is that this tech will overcome many of the current limitations of Tregs therapeutics, including rarity and plasticity of endogenous Tregs populations.

Regulatory T cells, or Tregs, play a key role in modulating other cells in the immune system so they don't attack the bodys own tissues. The failure of Tregs can lead to autoimmune diseases.

In a June paper published in the Science Translational Medicine journal, the team from the Seattle Childrens Research Institute and the Benaroya Research Institute made Treg-like cells by gene editing ordinary T cells to express Foxp3 and paired them with antigen-specific T cell receptors. The engineered cells prevented harmful autoimmune response in Type 1 diabetes in mice.

GentiBio is focused on addressing the technical bottlenecks that have throttled Treg therapeutics, and we are thrilled to exclusively in-license a portfolio of unprecedented breadth from Seattle Childrens and Benaroya Research Institute in the U.S. and MIGAL Galilee Research Institute in Israel, said Adel Nada, M.D., co-founder and CEO of GentiBio.

The technologies licensed from these premier research institutions are mature and well-differentiated, and will be further optimized in sponsored research collaborations with the scientific teams that discovered them to advance novel and potent therapeutics with the potential to treat and cure serious autoimmune and inflammatory diseases.

Tregs are rare cells within the immune system and current therapies that source Tregs cells from the blood stream can be costly and cumbersome. In contrast, Seattle Childrens unique technology enables the generation of engineered regulatory T cells, or EngTregs, from the more abundant CD4+ cell population, addressing a critical manufacturing shortcoming for this novel treatment, said David Rawlings, M.D., director, center for immunity and immunotherapies, Seattle Childrens Research Institute and scientific co-founder of GentiBio.

Go here to read the rest:
Novartis and a string of high profile backers fund next-gen Treg cell therapy startup GentiBio - FierceBiotech

Comments are closed.